Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,534 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Liver toxicity after switching or simplifying to nevirapine-based therapy is not related to CD4 cell counts: results of the TOSCANA study.
Antela A, Ocampo A, Gómez R, López MJ, Mariño A, Losada E, Rodríguez R, Fernández R, Corredoira JC, Naval G, Rodríguez A, Miralles C, Prieto A, Gevihga Galician HIV Study Group. Antela A, et al. Among authors: marino a. HIV Clin Trials. 2010 Jan-Feb;11(1):11-7. doi: 10.1310/hct1101-11. HIV Clin Trials. 2010. PMID: 20400407
Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients.
Núñez M, Mariño A, Miralles C, Berdún MA, Sola J, Hernandez-Burruezo JJ, Galindo MJ, Barreiro P, Martin-Carbonero L, Soriano V. Núñez M, et al. Among authors: marino a. J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):439-44. doi: 10.1097/QAI.0b013e318061b5d9. J Acquir Immune Defic Syndr. 2007. PMID: 17468669 Clinical Trial.
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E; GESIDA 3903 Team. Berenguer J, et al. Clin Infect Dis. 2008 Oct 15;47(8):1083-92. doi: 10.1086/592114. Clin Infect Dis. 2008. PMID: 18781872 Clinical Trial.
Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients.
Podzamczer D, Olmo M, Sanz J, Boix V, Negredo E, Knobel H, Domingo P, Pineda JA, Vilades C, Quero JH, Force L, Lahoz JG, Muñoz P, Llibre JM, Mariño A, Ortega E, Dalmau D, Gatell JM, Antón E, Sola J, Galindo MJ, Pedrol E, Sanz J, Lima JT, Flores J; NODy Study Group. Podzamczer D, et al. Among authors: marino a. J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):390-6. doi: 10.1097/QAI.0b013e318198a0cc. J Acquir Immune Defic Syndr. 2009. PMID: 19214120 Clinical Trial.
Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study).
Echeverría P, Negredo E, Carosi G, Gálvez J, Gómez JL, Ocampo A, Portilla J, Prieto A, López JC, Rubio R, Mariño A, Pedrol E, Viladés C, del Arco A, Moreno A, Bravo I, López-Blazquez R, Pérez-Alvarez N, Clotet B. Echeverría P, et al. Among authors: marino a. Antiviral Res. 2010 Feb;85(2):403-8. doi: 10.1016/j.antiviral.2009.11.008. Epub 2009 Nov 24. Antiviral Res. 2010. PMID: 19941906 Clinical Trial.
Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions.
Rubio R, Serrano O, Carmena J, Asensi V, Echevarría S, Flores J, Ribera E, Zarraga M, Ocampo A, de la Fuente B, Sepúlveda MA, Mariño AI, Minguez C, Vicent R, Cartón JA, Moyano B, Esteban H, Mahillo B, Serrano L, González-García J; GESIDA 44/04 SIMPATAZ Study Group. Rubio R, et al. Among authors: marino ai. HIV Med. 2010 Oct 1;11(9):545-53. doi: 10.1111/j.1468-1293.2010.00827.x. Epub 2010 Mar 19. HIV Med. 2010. PMID: 20345884 Free article.
Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
Revilla A, Delgado E, Christian EC, Dalrymple J, Vega Y, Carrera C, González-Galeano M, Ocampo A, de Castro RO, Lezaún MJ, Rodríguez R, Mariño A, Ordóñez P, Cilla G, Cisterna R, Santamaría JM, Prieto S, Rakhmanova A, Vinogradova A, Ríos M, Pérez-Álvarez L, Nájera R, Montefiori DC, Seaman MS, Thomson MM. Revilla A, et al. Among authors: marino a. AIDS Res Hum Retroviruses. 2011 Aug;27(8):889-901. doi: 10.1089/AID.2010.0177. Epub 2011 Feb 16. AIDS Res Hum Retroviruses. 2011. PMID: 21226626
Late initiation of HAART among HIV-infected patients in Spain is frequent and related to a higher rate of virological failure but not to immigrant status.
Pérez-Molina JA, Suárez-Lozano I, Del Arco A, Teira R, Bachiller P, Pedrol E, Martínez-Alfaro E, Domingo P, Mariño A, Ribera E, Antela A, de Otero J, Navarro V, González-García J; Gesida 5808 Study Group. Pérez-Molina JA, et al. Among authors: marino a. HIV Clin Trials. 2011 Jan-Feb;12(1):1-8. doi: 10.1310/hct1201-1. HIV Clin Trials. 2011. PMID: 21388936
1,534 results